astrazeneca hit drug failure share drug close uk trade failure iressa drug major clinical trial lung cancer drug significantly prolong survival patient disease setback group follow rejection u october pill exanta meanwhile another major money spinner cholesterol drug crestor face mount safety concern would two three blockbuster drug mean power company forward fail get risk crestor say nick turner analyst broker jefferies astrazeneca hop pitch iressa drug rival medicine tarceva iressa prove well placebo extend life trial involve patient tarceva make osi pharmaceutical genentech roche already prove successful help prolong life lung cancer patient aztrazeneca appoint new executive director board john patterson charge drug development company say mr patterson would make substantial change clinical organisation process determine improve development regulatory performance restore confidence company value shareholder say chief executive tom mckillop